Laekna (HKSE:02105) Issuance of Debt : HK$106.09 Mil (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Laekna Issuance of Debt?

Laekna's Issuance of Debt for the six months ended in Dec. 2024 was HK$60.56 Mil.

Laekna's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 was HK$106.09 Mil.

Laekna Issuance of Debt Historical Data

The historical data trend for Laekna's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laekna Issuance of Debt Chart

Laekna Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Issuance of Debt

2.45

21.94

59.50

105.71

Laekna Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Issuance of Debt	Get a 7-Day Free Trial			21.94	32.60	26.91	45.53	60.56

Laekna Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$106.09 Mil.

Laekna Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Laekna's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Laekna Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » Issuance of Debt

Comparable Companies

Traded in Other Exchanges

4U4:Germany

Address

No. 3-2-467, 5 Xingbin Road (Lin Li Center), Sino-Italy Ningbo Ecological Park, Zhejiang Province, Yuyao, CHN, 201203

Website

https://www.laekna.com

Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.

Executives

Orbimed Advisors Iii Limited	2102 Investment manager
Orbimed Asia Gp Iii, L.p.	2102 Investment manager
Orbimed Asia Partners Iii, L.p.	2102 Investment manager
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo	2101 Beneficial owner
Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si	2101 Beneficial owner
Laekna Wonderland Limited	2101 Beneficial owner
Lu Chris Xiangyang	2501 Other
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Gp Healthcare Capital, Inc.	2101 Beneficial owner
Liu Zeng	2201 Interest of corporation controlled by you
Ealex Llc	2101 Beneficial owner
Futu Trustee Limited	2301 Trustee

Laekna Headlines

No Headlines